Intel says its new Wildcat Lake Core 3 Series chip family is built for affordable laptops. My first wave of tests shows ...

Seriously, I'm sorry I had a gazillion browser tabs open alongside several hours' worth of unsaved work. Please don't crash.

The first Windows Secure Boot expiration date is here for more than a billion PCs, with more to come - and even some Linux ...

Amid the drama at the biotech, a new figure has stepped up right as the company needs a new long-term chief executive and chairman. Brian McNamee is CSL’s immovable object and unstoppable force. But ...

CSL shares have been hammered by earnings disappointments. But the long-term investment case remains strong. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium ...

In a 90-day review, CSL told the market it would take another $US5bn ($A6.9bn) non-cash impairment. The first $1.5bn of this was recognised during the first-half ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...

CSL shares crash after another profit warning rocks investor confidence. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley ...

CSL has lost the trust of major investors after slashing earnings forecasts reaffirmed three months ago and announcing one of the biggest write-downs in Australian corporate history as the healthcare ...

This article first appeared on GuruFocus. CSL Ltd. (CMXHF) suffered its sharpest share-price drop on record after the Australian biotechnology company cut its full-year outlook, warned that its ...

Shares in health giant CSL tanked today, with the stock closing 16 per cent lower, at $100.75. At earlier points in the session, the stock was down more than 20 per cent, sinking below $100 to decade ...

CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...